Journal ArticleDOI
Nephrotic syndrome after treatment with pamidronate
About:
This article is published in American Journal of Kidney Diseases.The article was published on 2002-05-01. It has received 55 citations till now. The article focuses on the topics: Pamidronic acid & Nephrotic syndrome.read more
Citations
More filters
Journal ArticleDOI
Randomized Phase III Trial of Capecitabine Compared With Bevacizumab Plus Capecitabine in Patients With Previously Treated Metastatic Breast Cancer
Kathy D. Miller,Linnea I. Chap,Frankie A. Holmes,Melody A. Cobleigh,P. Kelly Marcom,Louis Fehrenbacher,Maura N. Dickler,Beth Overmoyer,James D. Reimann,Amy P. Sing,Virginia K. Langmuir,Hope S. Rugo +11 more
TL;DR: Although the addition of bevacizumab to capecitabine produced a significant increase in response rates, this did not translate into improved PFS or overall survival.
Journal ArticleDOI
International Myeloma Working Group Recommendations for the Treatment of Multiple Myeloma–Related Bone Disease
Evangelos Terpos,Gareth J. Morgan,Meletios A. Dimopoulos,Matthew T. Drake,Suzanne Lentzsch,Noopur Raje,Orhan Sezer,Ramón García-Sanz,Kazuyuki Shimizu,Ingemar Turesson,Tony Reiman,Artur Jurczyszyn,Giampaolo Merlini,Andrew Spencer,Xavier Leleu,Michele Cavo,Nikhil C. Munshi,S. Vincent Rajkumar,Brian G.M. Durie,G. David Roodman +19 more
TL;DR: The International Myeloma Working Group (IMWG) developed practice recommendations for the management of multiple myeloma (MM)related bone disease as discussed by the authors, and the levels of evidence and grades of recommendations were assigned and approved by panel members.
Journal ArticleDOI
Management of the adverse effects associated with intravenous bisphosphonates
TL;DR: Prescribing clinicians should be familiar with these possible adverse effects of intravenous bisphosphonates and discuss them with patients before commencing or continuing on therapy.
Journal ArticleDOI
The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network.
Evangelos Terpos,Evangelos Terpos,Orhan Sezer,Peter I. Croucher,Ramón García-Sanz,Mario Boccadoro,J F San Miguel,J. Ashcroft,J. Bladé,Michele Cavo,Michel Delforge,Meletios A. Dimopoulos,Thierry Facon,Margaret Macro,Anders Waage,Pieter Sonneveld +15 more
TL;DR: BPs are an essential component of MM therapy for minimizing skeletal morbidity and a modified dosing regimen and preventive measures can greatly reduce the incidence of ONJ.
Journal ArticleDOI
Renal Failure Associated with Cancer and Its Treatment: An Update
TL;DR: This chemoreception study highlights the need to select patients suitable for routine or laparoscopic excision for this type of surgery on the basis of prior history and once they provide informed consent for surgery.
References
More filters
Journal ArticleDOI
The small GTP-binding protein rac regulates growth factor-induced membrane ruffling.
TL;DR: It is proposed that rac and rho are essential components of signal transduction pathways linking growth factors to the organization of polymerized actin and that growth factors act through rac to stimulate this rho-dependent response.
Journal ArticleDOI
Protein prenylation: molecular mechanisms and functional consequences.
Fang L. Zhang,Patrick J. Casey +1 more
TL;DR: The emphasis in this review is on the enzymology of prenyl protein processing and the functional significance ofPrenylation in cellular events.
Journal ArticleDOI
Efficacy of Pamidronate in Reducing Skeletal Events in Patients with Advanced Multiple Myeloma
James R. Berenson,Alan Lichtenstein,Lester Porter,Meletios A. Dimopoulos,Roldolfo Bordoni,Sebastian George,Allan Lipton,Alan Keller,O. F. Ballester,Michael J. Kovacs,Hilary A. Blacklock,Richard Bell,Joseph F. Simeone,Dirk J. Reitsma,Maika Heffernan,John J. Seaman,Robert Knight +16 more
TL;DR: Monthly infusions of pamidronate provide significant protection against skeletal complications and improve the quality of life of patients with stage III multiple myeloma.
Journal ArticleDOI
Cellular and molecular mechanisms of action of bisphosphonates
Michael J. Rogers,Sharon Gordon,H L Benford,Fraser P. Coxon,S. P. Luckman,Jukka Mönkkönen,Julie C. Frith +6 more
TL;DR: Bisphosphonates currently are the most important class of antiresorptive agents used in the treatment of metabolic bone diseases, including tumor‐associated osteolysis and hypercalcemia, Paget's disease, and osteoporosis.